CLOSTRIDIUM VACCINE MARKET ANALYSIS

Market Challenges And Opportunities

Clostridium Vaccine Market Drivers

Rising incidence and high prevalence of clostridium difficile infection is expected to boost growth of the market over the forecast period. Incidence of clostridium difficile infection has been witnessing an increase since the recent past, due to its infection recurrence and antibiotic resistance. According to Centers for Disease Control and Prevention (CDC), in 2015 around half a million people in the U.S. suffer from clostridium difficile infection in a year.

Moreover, according to National Center for Biotechnology Information (NCBI), an estimated 37,900 patients were suffering from clostridium difficile infection in Canada in 2012. A review and meta-analysis of studies published in National Center for Biotechnology Information (NCBI), 2016, conducted in China between 2010 and 2016, reported significant incidence of clostridium difficile infection in China.

Clostridium Vaccine Market Restraint

Increased risk associated with the failure of vaccine candidate during the clinical trial studies and high cost associated with late stage testing is expected to slow down commercialization of clostridium vaccine and restrain the clostridium vaccine market growth over the forecast period.

For instance, in December 2017, Sanofi terminated its phase III C. difficile clinical trial studies, due to the results of an interim trial analysis, which stated low probability of success with its C. difficile candidate. Moreover, discontinuation of Sanofi’s C. difficile vaccine program is expected to offer great future opportunity for Pfizer and Valneva to offer its vaccine to patients after getting the satisfactory regulatory approval in the future.